GSK's TYKERB(R) Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer
Links shared publicly online about this topic.
- 1,411total visits
GSK's TYKERB(R) Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer
GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line
View full resource at medicalnewstoday.com
Tags: Cancer, Breast Cancer, Metastatic Breast Cancer, Drug, Women's Health, FDA, GlaxoSmithKline
Most Recently Shared on February 2, 2010 at 6:10 pm By:
GSK's TYKERB(R) Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer http://mnt.to/3x4y
Also Shared By:
GSK’s TYKERB receives accelerated approval for first-line combination treatment of metastatic breast cancer
us.gsk.com — “not named” View full resource at us.gsk.com
Most Recently Shared on February 1, 2010 at 2:33 pm By:
eyeonfda Pharma and Health Lawyer
GSK’s TYKERB receives accelerated approval for first-line combination treatment of metastatic breast cancer - http://ow.ly/12ytk
Advertisement
MNT Breast Cancer
@mnt_breastcance
GSK's TYKERB(R) Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer http://mnt.to/3x4y
1 year ago...